The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMW 2021 | Defining high-risk myeloma
Jill Corre, PharmD, PhD, of L’Institut Universitaire du Cancer de Toulouse-Oncopole, Centre Hospitalier Universitaire, Toulouse, France, talks on defining high-risk myeloma and describes how the microenvironment, plasma cells, immune cells, and cytogenetics are used to define risk. In particular, Dr Corre talks on a study which demonstrated that disease aggression was correlated with the number of adverse cytogenetic features. Dr Corre also discusses the difficulties with attributing the role of individual mutations to disease development or progression. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
